Treatment patterns and outcomes in CLL/SLL after BTK inhibitor exposure using a Japanese claims database

The covalent Bruton tyrosine kinase inhibitor (cBTKi), ibrutinib (IBR), and B-cell lymphoma-2 inhibitor (BCL-2i), venetoclax, were recently approved in Japan for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Treatment options following cBTKi are limited. This study investigated characteristics, treatment patterns, and outcomes of patients with CLL/SLL following cBTKi exposure using a Japanese real-world database.